Gilead's revenue at $5.1B in Q2

Thursday, 30. July 2020 22:04

Gilead Sciences reported on Thursday that the company's revenue in the second quarter of fiscal 2020 landed at $5.14 billion, marking a 10% fall compared to the same period a year before. In the three-month period ended June 30, Gilead’s GAAP diluted loss per share landed at $2.66, while adjusted diluted earnings per share stood at $1.11.

In the first half of fiscal 2020, the drugmaker reported revenue of $10.5 billion, 3% less compared to the same period last year, while its diluted loss per share amounted to $1.42 in six months ended on the last day of June.

"Gilead’s first half performance demonstrates the strength and durability of our core HIV business, even as we navigated the expected impact of the COVID-19 pandemic. We are already starting to see early signs of recovery from this impact and we are fully confident in our long-term HIV leadership," said Gilead CEO Daniel O’Day.

Related Links: 
Breaking the News / BU